Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Curis Lifesciences IPO
Price Band
₹120.0–128.0
Issue Size
₹27.52 Cr
Lot Size
1,000 shares
Min Investment
₹256,000
2 LOTS MIN
GMP
+₹9.0 (7.03%)
Issue Price
₹128.0
Subject to Sauda
₹6800
Paid only if allotted
Curis Lifesciences IPO AI Summary
- Curis Lifesciences IPO is listed on NSE SME in the Pharmaceuticals sector.
- Price band: ₹120.0–₹128.0 per share, lot size 1,000 shares (min. investment ₹256,000, 2 lots minimum).
- Subscription window: 07 Nov–11 Nov 2025, listing on 14 Nov 2025.
- Current GMP is +₹9.0 (7.03%), an estimated listing price of ₹137 — unofficial and can change daily.
Curis Lifesciences Limited is set to launch its IPO with a price band of ₹120 to ₹128, aiming to raise ₹27.52 Cr. The company has shown strong growth in profit margins and has a solid operational framework, although recent income figures indicate some volatility. Investors should consider their risk tolerance and investment strategy when evaluating this IPO.
TopFund is not SEBI-registered — this is educational analysis, not personalized investment advice.
Curis Lifesciences IPO — Third-Party Research Views
Reviews below reflect analyst calls made before this IPO closed on 11 Nov 2025 — not a current signal.
Recommendations are sourced from third-party research firms and are not TopFund's own investment advice.
Important Dates
Subscription Status
Subscription data unavailable
Curis Lifesciences IPO Grey Market Premium (GMP) Today
GMP
+₹9.0
GMP %
+7.03%
Est. Listing
₹137.0
Updated: 25 Jul 2026 14:15
About the Company
Incorporated in 2010, Curis Lifesciences Limited is a pharmaceutical company that specializes in developing, manufacturing, and distributing a diverse range of products. The company manufactures pharmaceutical products globally and domestically on a loan license or contract basis, as well as for its own brand marketing. The company serves over 100 corporate clients on loan licenses or contract manufacturing and 2 clients for its own brand marketing in Yemen and Kenya. Products: General pharmaceutical tablets and capsules Oral liquids External preparations Sterile ophthalmic ointments The company operates a state-of-the-art manufacturing facility in Sanand, Gujarat, adhering to stringent quality control measures to ensure product safety and efficacy. As of July 31, 2025, the company has 95 permanent employees. Competitive Strengths: Experienced Promoters and Management Team Wide range of Products Strategic Location of Manufacturing Facility Scalable Business Model Quality assurance
Company Financials (₹ Cr)
As of 2025-07-31
| Period Ended | 31 Jul 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 56.29 | 42.53 | 33.88 | 29.75 |
| Total Income | 19.51 | 49.65 | 35.87 | 36.42 |
| Profit After Tax | 2.87 | 6.11 | 4.87 | 1.88 |
| EBITDA | 4.24 | 9.54 | 8.39 | 3.28 |
| NET Worth | 19.10 | 16.23 | 5.87 | 1.01 |
| Reserves and Surplus | 13.16 | 10.29 | 5.37 | 0.51 |
| Total Borrowing | 15.32 | 15.62 | 17.09 | 16.19 |
Key Ratios
EPS
₹10.29
NAV
₹27.34
ROE
55.25%
ROCE
27.83%
RoNW
37.62%
P/B Value
12.64
P/E Ratio
12.44
Market Cap
₹103.48 Cr
PAT Margin
12.43%
Debt/Equity
0.96
Peer Comparison
| Company | NAV | RoNW | P/E (x) | EPS Basic | EPS Diluted |
|---|---|---|---|---|---|
| Lincoln Pharmaceuticals Limited | 335.34 | 12.27% | 12.21 | 41.11 | 41.11 |
| Sotac Pharmaceuticals Limited | 47.99 | 9% | 18.3 | 4.32 | 4.32 |
| Curis Lifesciences Limited This IPO | 27.34 | 37.62% | — | 10.29 | 10.29 |
Promoters
Dharmesh Dashrathbhai Patel, Siddhant Jayantibhai Pawasia, Piyush Gordhanbhai Antala and Jaimik Mansukhbhai Patel
Objects of the Issue
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects: # Issue Objects Est Amt (₹ Cr.) 1 Capital Expenditure towards Upgradation/Improvement of the existing Manufacturing Facilities 2.44 2 Capital Expenditure towards Construction of a Storage Facility 3.62 3 Pre-payment/Repayment of outstanding Secured Loans 1.86 4 Product Registrations in other countries 2.69 5 Funding working capital requirements 11.25 6 General Corporate Purposes 2.85 7 Issue Expenses 2.80 Total 27.52
IPO Evaluation
Generated 23 Sep 2026Revenue Trend
Total income was ₹36.42 Cr in the year ended 31 Mar 2023, increasing to ₹35.87 Cr by 31 Mar 2024. However, it rose significantly to ₹49.65 Cr by 31 Mar 2025, before dropping to ₹19.51 Cr by 31 Jul 2025, though this is a 9-month figure, not a full year, so isn't directly comparable.
Profit Trend
Profit after tax was ₹1.88 Cr in the year ended 31 Mar 2023, rising to ₹4.87 Cr by 31 Mar 2024. It further increased to ₹6.11 Cr by 31 Mar 2025, before falling to ₹2.87 Cr by 31 Jul 2025, though this is a 9-month figure, not a full year, so isn't directly comparable.
Valuation
Curis Lifesciences has an EPS of ₹10.29 and a P/E ratio of 12.44, implying it is priced at roughly 12.44 trailing earnings. In comparison, peers are trading at P/E ratios ranging from 12.21 to 18.3.
Grey Market Premium, Explained
The Grey Market Premium (GMP) indicates the price at which shares are expected to trade in the grey market before they are officially listed. A positive GMP suggests that investors expect the stock to list at a higher price than the issue price, while a negative GMP indicates the opposite.
Who This IPO Suits
Investors comfortable with short-term volatility and a long-term horizon typically weigh IPOs like this against their overall investment strategy, considering factors such as market conditions and the company's growth potential.
Who May Want to Wait
Investors who prefer stable returns and lower risk may want to avoid IPOs like this, which can be subject to significant price fluctuations and market uncertainty.
IPO Timeline, Explained
The IPO opens for subscription on 7 November 2025 and closes on 11 November 2025. Allotment of shares will be done on 12 November 2025, with the listing date set for 14 November 2025.
Listing Gains — The Risk
Listing-day gains can be unpredictable and are influenced by various factors, including market sentiment and demand for the stock. Investors should be prepared for the possibility of price volatility on the listing day.
This evaluation is generated from Curis Lifesciences's own public IPO filing data for educational purposes and is not investment advice or a recommendation to apply, subscribe to, or avoid this issue — see Broker Recommendations below for named third-party research views (clearly attributed, not TopFund's own). TopFund is not a SEBI-registered investment adviser — see our Disclaimer.
Frequently Asked Questions
What is Curis Lifesciences IPO GMP today?
Curis Lifesciences IPO GMP today is +₹9.0 (7.03%), indicating an estimated listing price of ₹137. GMP is an unofficial grey-market indicator and can change daily.
What is the price band of Curis Lifesciences IPO?
The price band of Curis Lifesciences IPO is ₹120.0–₹128.0 per share.
When does Curis Lifesciences IPO open and close?
Curis Lifesciences IPO opens on 07 November 2025 and closes on 11 November 2025.
When does Curis Lifesciences IPO list on the stock exchange?
Curis Lifesciences IPO listed on 14 November 2025 at ₹137.0.
What is the lot size for Curis Lifesciences IPO?
The lot size for Curis Lifesciences IPO is 1000 shares, requiring a minimum investment of ₹256,000 (2 lots).
What is the price band for the IPO?
The price band for the IPO is ₹120 to ₹128.
What is the minimum investment required?
The minimum investment required is ₹256,000.
What is the lot size for this IPO?
The lot size for this IPO is 1000 shares.
When is the listing date?
The listing date is 14 November 2025.
What does GMP mean?
GMP stands for Grey Market Premium, which indicates the expected price at which shares may trade in the grey market before listing.
Issue Details
Investor Allocation
Registrar
Lead Managers / Book Running
IPO Timeline
Open
07 Nov 2025
Close
11 Nov 2025
Allotment
12 Nov 2025
Listing
14 Nov 2025
Similar IPOs in Pharmaceuticals
Plan Your IPO Investment
Related Articles
Community Sentiment
What are other investors planning for Curis Lifesciences?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
No comments yet — start the discussion.